Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, and Chief Executive Officer, Gyo Sagara; “ONO”) today announced that there were differences in the non-consolidated financial results (Japanese standard) between the fiscal year ended March 2022 (April 1, 2021 to March 31, 2022) and previous fiscal year.

1. Differences in the full-year non-consolidated financial results between the fiscal year ended March 2022 and the previous fiscal year

   (Unit: Millions of yen, except basic earnings per share)

   	Sales	Operating Profit	Ordinary Profit	Net Profit for the year	Basic earnings per share（yen）
   Previous Results(A) (FY ended March 2021)	305,183	84,929	86,778	76,927	154.10
   Actual Results(B) (FY ended March 2022)	357,023	119,899	121,057	94,594	190.51
   Change（B－A）	51,840	34,970	34,279	17,667	-
   Change（％）	17.0	41.2	39.5	23.0	-

2. Reasons for the differences
   　Because of the growth in sales of main products such as Opdivo Intravenous Infusion for malignant tumors, and Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease, etc., as well as an increase in royalty revenue, there were differences in the full-year non-consolidated financial results between the fiscal year ended March 31, 2022 and the previous fiscal year.